Find disease awareness content and relevant supporting materials

Researchers reported the first human use of a transcatheter coronary artery bypass procedure performed without opening the chest. Separately, new markers improved detection of circulating triple-negative breast cancer cells, and varenicline reduced cannabis use in men with cannabis use disorder.

This ASCO living guideline synthesises evidence on systemic treatment selection for patients with stage I-III hormone receptor-positive, HER2-negative breast cancer. Recommendations address the use and sequencing of endocrine therapy, chemotherapy and targeted therapies, with treatment decisions guided by tumour characteristics, genomic testing, recurrence risk and patient preferences.

Follow all the latest developments with daily highlights from the European Society of Medical Oncology Breast Cancer Congress in Berlin, Germany, 3–5 May 2022.

The Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending a change to the terms of the marketing authorisation for the medicinal product Keytruda (pembrolizumab) from Merck Sharp & Dohme for triple negative breast cancer.

Join Professor Nadia Harbeck, Director of the Breast Centre at LMU University Hospital in Munich, Germany, as she shares her insights on the key developments for breast cancer treatment that emerged at ESMO Breast Cancer 2022.

The European Society for Medical Oncology (ESMO) has released expert consensus statements on HER2-low breast cancer, a newly recognized and targetable subtype. These statements address biology, diagnosis, treatment, and clinical trial design, aiming to guide oncologists in managing HER2-low metastatic disease.

Samsung Bioepis Co. Ltd. announced that Health Canada has approved Ontruzant (also known as SB3), a biosimilar referencing Herceptin (Trastuzumab), for the treatment of adults with Early Breast Cancer (EBC), Metastatic Breast Cancer (MBC) and metastatic gastric cancer (MGC).

National Institute for Health and Care Excellence (NICE) recommends;Tucatinib with trastuzumab and capecitabine for treating HER2-positive advanced breast cancer after 2 or more anti-HER2 therapies Technology appraisal guidance [TA786]Published: 27 April 2022.

Follow all the latest developments with daily highlights from the European Society of Medical Oncology Breast Cancer Congress in Berlin, Germany, 3–5 May 2022.

The Pan-Asian adapted ESMO guidelines provide region-specific recommendations for diagnosing, staging, and treating metastatic breast cancer (MBC). Developed by experts from 10 Asian oncology societies, these consensus statements aim to harmonize care across Asia while accounting for genetic, demographic, and access-related differences.